-
1دورية أكاديمية
المؤلفون: Avogaro A., Azzolina D., Gregori D., De Kreutzenberg S., Fadini G. P., Mannucci E.
المساهمون: Avogaro, A., Azzolina, D., Gregori, D., De Kreutzenberg, S., Fadini, G. P., Mannucci, E.
مصطلحات موضوعية: Diabetes mellitu, Glucagon-like peptide 1 receptor agonist, Heart failure, NT-proBNP concentration, Body Weight, Glycated Hemoglobin A, Human, Hypoglycemic Agent, Natriuretic Peptide, Brain, Peptide Fragment, Diabetes Mellitus, Type 2, Glucagon-Like Peptide-1 Receptor
الوصف: Aims: Glucagon-like peptide 1 receptor agonists (GLP-1RA) decrease the risk of major adverse cardiovascular events (MACE). However, their influence on the risk of heart failure (HHF) hospitalization is marginal, which is unexpected given their benefits on cardiometabolic risk, especially on bodyweight reduction. This meta-analysis aimed to map the effects of GLP-1RA on N-terminal pro-BNP. Methods and results: We retrieved from a Medline and Embase all randomized trials comparing GLP-1RA with placebo, reporting NT-proBNP concentrations. The primary outcome was the change in N-terminal pro-BNP values from baseline to end-of-treatment with GLP-1RA versus placebo (reported as standard deviations, SD). We included nine trials (543 patients in active treatment and 536 in placebo). We observed significantly greater reductions in N-terminal pro-BNP with GLP-1RA versus placebo (−0.14 SD; 95% CI −0.27; −0.01; p = 0.03). Upon meta-regression, no modifying effect of age, HbA1c, and body mass index were observed, nor was any meta-correlation between the change in NT-proBNP and the change in HbA1c or body weight. Conclusions: GLP-1RA can significantly decrease N-terminal pro-BNP. This effect was independent of baseline age, body weight, and metabolic control.
العلاقة: info:eu-repo/semantics/altIdentifier/pmid/35306033; info:eu-repo/semantics/altIdentifier/wos/WOS:000806170400020; volume:357; firstpage:123; lastpage:127; numberofpages:5; journal:INTERNATIONAL JOURNAL OF CARDIOLOGY; http://hdl.handle.net/11577/3451487Test; info:eu-repo/semantics/altIdentifier/scopus/2-s2.0-85126916466
-
2دورية أكاديمية
المؤلفون: Bunevičius, Adomas, Deltuva, Vytenis Pranas, Laws, Edward R, Iervasi, Giorgio, Tamašauskas, Arimantas, Bunevičius, Robertas
المصدر: Scientific reports, London : Nature Publishing Group, 2017, vol. 7, no. 1, 14775, p. 1-8 ; eISSN 2045-2322
مصطلحات موضوعية: Brain tumor, Surgery, N-terminal pro-B-type natriuretic peptide (NT-proBNP) concentration, info:eu-repo/classification/udc/616.831-006.6
الوصف: Increased N-terminal pro-B-type natriuretic peptide (NT-proBNP) concentration predicts poor prognosis of non-CNS cancer patients. We evaluated the association of NT-proBNP concentration with disease severity, discharge outcomes and prognosis of patients undergoing craniotomy for brain tumor. From January, 2010 until September, 2011 two-hundred and forty-five patients (age 55.05 ± 14.62 years) admitted for brain tumor surgery were evaluated for NT-proBNP serum concentration. Outcome at hospital discharge was evaluated with the Glasgow Outcome Scale (GOS). Most common diagnoses were meningioma (37%) and high-grade glioma (20%). Greater NT-proBNP concentration was associated with lower Barthel index (rho = -0.305, p = 0.001) and Mini Mental State Examination scores (rho = -0.314, p = 0.001) and with greater Hospital Anxiety and Depression scale Depression score (rho = 0.240, p = 0.026). Greater admission NT-proBNP concentration was associated with lower discharge GOS score after adjusting for patient age, gender and histological brain tumor diagnosis (β = -0.253, p < 0.001). Greater NT-proBNP concentration was also associated with greater 5-year mortality risk (HR = 1.845; 95%CI [1.166-2.920], p = 0.009) controlling for patient age, gender, history of cardiovascular disease, histological diagnosis and adjuvant therapy. In sum, greater pre-operative NT-proBNP concentration is associated with worse health status, unfavorable discharge outcome and shorter survival of brain tumor patients.
-
3دورية أكاديمية
المؤلفون: Bunevičius, Adomas, Deltuva, Vytenis Pranas, Laws, Edward R, Iervasi, Giorgio, Tamašauskas, Arimantas, Bunevičius, Robertas
المصدر: Scientific reports, London : Nature Publishing Group, 2017, vol. 7, no. 1, 14775, p. 1-8 ; eISSN 2045-2322
مصطلحات موضوعية: Brain tumor, Surgery, N-terminal pro-B-type natriuretic peptide (NT-proBNP) concentration, info:eu-repo/classification/udc/616.831-006.6
الوصف: Increased N-terminal pro-B-type natriuretic peptide (NT-proBNP) concentration predicts poor prognosis of non-CNS cancer patients. We evaluated the association of NT-proBNP concentration with disease severity, discharge outcomes and prognosis of patients undergoing craniotomy for brain tumor. From January, 2010 until September, 2011 two-hundred and forty-five patients (age 55.05 ± 14.62 years) admitted for brain tumor surgery were evaluated for NT-proBNP serum concentration. Outcome at hospital discharge was evaluated with the Glasgow Outcome Scale (GOS). Most common diagnoses were meningioma (37%) and high-grade glioma (20%). Greater NT-proBNP concentration was associated with lower Barthel index (rho = -0.305, p = 0.001) and Mini Mental State Examination scores (rho = -0.314, p = 0.001) and with greater Hospital Anxiety and Depression scale Depression score (rho = 0.240, p = 0.026). Greater admission NT-proBNP concentration was associated with lower discharge GOS score after adjusting for patient age, gender and histological brain tumor diagnosis (β = -0.253, p < 0.001). Greater NT-proBNP concentration was also associated with greater 5-year mortality risk (HR = 1.845; 95%CI [1.166-2.920], p = 0.009) controlling for patient age, gender, history of cardiovascular disease, histological diagnosis and adjuvant therapy. In sum, greater pre-operative NT-proBNP concentration is associated with worse health status, unfavorable discharge outcome and shorter survival of brain tumor patients.
